

27 August 2014

The Manager
Company Announcements Office
ASX Limited
Level 6, 20 Bridge Street
SYDNEY NSW 2000

Appointment of Clinical Development Advisors

27 August 2014 – Actinogen, an Australian biotechnology company, is pleased to announce the proposed appointment of Professor Alan Boyd (founder of Corticrine) and Professor Brian Walker (original inventor of UE2343) who will be joining Actinogen's Scientific and Clinical Development Advisory Panel.

Professor Alan Boyd

Professor Alan Boyd is a co-founder of Corticrine Ltd. Alan began his 30 years' pharmaceutical career with Glaxo Group Research Ltd. From 1988 he led ICI's cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.

In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals (now Astra Zeneca), he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for the development of their gene based medicines portfolio. In 2005 Alan set up Boyd Consultants. The focus of which is to aid and support early stage life-science based companies.

A graduate in Biochemistry and Medicine from the University of Birmingham, UK Professor Boyd is a Vice-President of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK. Professor Boyd is also an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School.

Professor Brian Walker

Brian Walker is clinical Professor of Endocrinology and Head of the University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science.

His prolific translational research over 20 years has concerned the role of glucocorticoids in metabolic syndrome and cardiovascular disease. He published the original description of 11 β -HSD1 as an amplifier of glucocorticoid action, identifying this enzyme as a prime therapeutic target (Corticrine lead compound, UE2343 is a patented novel inhibitor of 11 β -HSD1).

Professor Walker co-chairs the CORTisol NETwork (CORNET) international consortium that has conducted GWAS metanalyses for cortisol. He is Co-Director of the Edinburgh Clinical Academic Training (ECAT) scheme, mentor to its many recruits in various disciplines, former chair of the development group of the Edinburgh MSc in Translational Medicine, and has been a member of the Wellcome Trust's Clinical Interview Committee since 2007. He has extensive experience collaborating with and advising for pharmaceutical R&D.

-end-

Dr Brendan de Kauwe
Executive Director
Actinogen Limited

About Actinogen Limited

Actinogen Limited (ASX: ACW)

Actinogen is a clinical stage Australian biotechnology company focused on the development of novel treatments for Alzheimer's Disease (AD) and other major age-related neurodegenerative disorders. Actinogen's lead candidate UE2343 is a small molecule inhibitor of 11-beta-hydroxysteroid dehydrogenase (11 β -HSD1) an enzyme that reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. There is evidence for a role of glucocorticoids and hypothalamus-pituitary-adrenal axis dysfunction in AD that includes both cortisol-induced neurotoxicity on the hippocampal formation and acute ongoing impairment of cognition. UE2343 was discovered in 2007 at the laboratory of Professor Brian Walker at the University of Edinburgh. Subsequently, the University received significant support from the Wellcome Trust's Seeding Drug Discovery program to advance UE2343 into early clinical development.

In addition, the company has an early stage drug discovery program focused on developing drugs to treat brain cancer and potentially other oncological diseases by the targeted killing of cancer stem cells (CSCs). The first study was conducted in collaboration with Curtin University and the results demonstrated substantial reduction of proliferation in CSCs populations in glioblastoma cell lines.